Literature DB >> 28450237

A CRISPR-Cas9 Generated MDCK Cell Line Expressing Human MDR1 Without Endogenous Canine MDR1 (cABCB1): An Improved Tool for Drug Efflux Studies.

Maria Karlgren1, Ivailo Simoff2, Maria Backlund3, Christine Wegler4, Markus Keiser5, Niklas Handin2, Janett Müller5, Patrik Lundquist2, Anne-Christine Jareborg6, Stefan Oswald5, Per Artursson3.   

Abstract

Madin-Darby canine kidney (MDCK) II cells stably transfected with transport proteins are commonly used models for drug transport studies. However, endogenous expression of especially canine MDR1 (cMDR1) confounds the interpretation of such studies. Here we have established an MDCK cell line stably overexpressing the human MDR1 transporter (hMDR1; P-glycoprotein), and used CRISPR-Cas9 gene editing to knockout the endogenous cMDR1. Genomic screening revealed the generation of a clonal cell line homozygous for a 4-nucleotide deletion in the canine ABCB1 gene leading to a frameshift and a premature stop codon. Knockout of cMDR1 expression was verified by quantitative protein analysis and functional studies showing retained activity of the human MDR1 transporter. Application of this cell line allowed unbiased reclassification of drugs previously defined as both substrates and non-substrates in different studies using commonly used MDCK-MDR1 clones. Our new MDCK-hMDR1 cell line, together with a previously developed control cell line, both with identical deletions in the canine ABCB1 gene and lack of cMDR1 expression represent excellent in vitro tools for use in drug discovery.
Copyright © 2017 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ABC transporters; MDCK cells; P-glycoprotein; drug transport; efflux pumps; genomics; membrane transporter; multidrug resistance transporters; permeability; proteomics

Mesh:

Substances:

Year:  2017        PMID: 28450237     DOI: 10.1016/j.xphs.2017.04.018

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

Review 1.  Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective.

Authors:  Avner Schlessinger; Matthew A Welch; Herman van Vlijmen; Ken Korzekwa; Peter W Swaan; Pär Matsson
Journal:  Clin Pharmacol Ther       Date:  2018-08-30       Impact factor: 6.875

Review 2.  Application of CRISPR-Cas9 System to Study Biological Barriers to Drug Delivery.

Authors:  Ji He; Riya Biswas; Piyush Bugde; Jiawei Li; Dong-Xu Liu; Yan Li
Journal:  Pharmaceutics       Date:  2022-04-20       Impact factor: 6.525

3.  Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein.

Authors:  Ruchika Bajaj; Lisa B Chong; Ling Zou; Eleftheria Tsakalozou; Zhanglin Ni; Kathleen M Giacomini; Deanna L Kroetz
Journal:  AAPS J       Date:  2021-09-15       Impact factor: 3.603

4.  Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).

Authors:  Xin Chen; Jashvant D Unadkat; Qingcheng Mao
Journal:  Drug Metab Dispos       Date:  2021-07-29       Impact factor: 3.579

5.  Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV.

Authors:  Ahizechukwu C Eke; Adeniyi Olagunju; Brookie M Best; Mark Mirochnick; Jeremiah D Momper; Elaine Abrams; Martina Penazzato; Tim R Cressey; Angela Colbers
Journal:  Clin Pharmacokinet       Date:  2020-10       Impact factor: 6.447

6.  Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability.

Authors:  Chiara Borsari; Erhan Keles; Andrea Treyer; Martina De Pascale; Paul Hebeisen; Matthias Hamburger; Matthias P Wymann
Journal:  RSC Med Chem       Date:  2021-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.